Skip to main content
Log in

ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to John Vetto MD, FACS, FAACE.

Ethics declarations

Disclosures

Jonathan S. Zager received research funding from Amgen, Castle Biosciences, Delcath Systems, Novartis, Provectus, and Philogen; serves on the medical advisory board for Delcath Systems, is a member of the speakers’ bureau for Sun Pharma and Pfizer; and is a consultant for Merck, Sanofi/Regeneron, Amgen, and Castle Biosciences. John T. Vetto is a speaker for Castle Biosciences. The remaining authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Dale Han: Deceased

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, S., Han, G., Elenwa, F. et al. ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?. Ann Surg Oncol 29, 2869–2870 (2022). https://doi.org/10.1245/s10434-021-11300-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-11300-7

Navigation